Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced a collaboration to develop a human chronic cardiac fibrosis model for advancing Aramchol-based therapeutics for fibrotic heart diseases.

The partnership will focus on creating a platform to study chronic post-myocardial infarction remodeling and heart failure with preserved ejection fraction (HFpEF). The model aims to examine the relationship between lipid metabolism, SCD1 enzyme activity, fibrosis, and tissue repair mechanisms.

Cardiac fibrosis represents a significant medical challenge as a major contributor to chronic heart failure. The condition currently lacks approved therapies that directly reverse the fibrotic process. The collaboration addresses limitations in existing research models that often fail to capture long-term disease progression in human patients.

The platform will combine Tissue Dynamics' vascularized cardiac organoids with embedded metabolic sensors and automated monitoring systems. The DynamiX platform can test more than 20,000 human organoids simultaneously, providing real-time data on metabolism, fibrosis, electrical conduction, and other disease-related pathways.

Galmed plans to apply its expertise in SCD1 biology and metabolic pathway modulation to investigate how lipid imbalances affect cardiac tissue repair and function. The companies intend to use artificial intelligence-driven analysis to evaluate Aramchol-based treatment candidates and dosing strategies.

"We believe that combining Tissue Dynamics' human cardiac organoid technology, embedded sensors, automation, and AI with Galmed's expertise in modulating fibrotic pathways gives us a unique opportunity to change how cardiac fibrosis therapies are developed," said Dr. Avner Ehrlich, CEO of Tissue Dynamics.

Galmed is a clinical-stage biopharmaceutical company that has primarily focused on developing Aramchol for liver disease treatment and is expanding into oncological and cardiometabolic applications.